- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03192072
A Rapid Test for Acute Respiratory Illness (Radical)
Evaluation of a Rapid Diagnostic Test for the Categorization of Acute Respiratory Illness
The primary purpose of this study is to support the development of a host response test for acute respiratory illness to identify bacterial, viral or NB/NV etiologies as compared to a clinical adjudication reference standard.
Secondary objectives include:
- Evaluate the effect of age on the performance of the HR-ARI test
- Evaluate the effect of race/ethnicity on the performance of the HR-ARI test
- Evaluate the effect of geography on the performance of the HR-ARI test
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The primary purpose of this study is to support the development of a host response test for acute respiratory illness to identify bacterial, viral or NB/NV etiologies as compared to a clinical adjudication reference standard.
Secondary objectives include:
- Evaluate the effect of age on the performance of the HR-ARI test
- Evaluate the effect of race/ethnicity on the performance of the HR-ARI test
- Evaluate the effect of geography on the performance of the HR-ARI test
Subjects will be identified in the Emergency Department of participating hospitals. Samples including nasopharyngeal swab, throat swab, blood, and urine will be obtained.
A case report form for each subject will be completed to include information regarding clinical characteristics, signs and symptoms of infection, presence of complications, and patient outcome. Baseline characteristics including preexisting conditions. Survival data will also be collected for each subject.
Samples collected will be used to characterize the patient's illness as either infectious or not, and if infectious, either bacterial or viral. Samples will also be used to measure changes in gene expression, referred to as the Host Response-Acute Respiratory Illness (HR-ARI) test.
The result of this test will be made in comparison to a retrospective review of the subject's clinical information. Results will not be used for any interventions and will not be released to subjects or their providers.
Because the study procedure includes only sample and data collection, the risks will be minimal and no different than encountered during routine clinical care.
The study was re-assessed in 2020 and applicable updates were made to the record.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
California
-
Davis, California, Stati Uniti, 95616
- The University of California- Davis
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Brigham and Women's Hospital
-
Newton, Massachusetts, Stati Uniti, 02462
- Newton-Wellesley Hospital
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- The University of North Carolina at Chapel Hill
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- Children's Hospital of Pittsburgh
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Rhode Island/Lifespan
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- The University of Texas- Houston
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84132
- University of Utah Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
A. Age 24 months or older
B. Acute respiratory illness of less than 28 days in duration.
C. Acute respiratory illness will be defined by at least two qualifying symptoms OR one qualifying symptom and at least 1 qualifying vital sign abnormality:
- Qualifying symptoms:Headache, rhinorrhea, nasal congestion, sneezing, sore throat, itchy or watery eyes, conjunctivitis, cough, shortness of breath, sputum production, chest pain, wheezing
- Qualifying Vital Signs: Age greater than or equal to 2 and less than 6:Tachycardia (HR greater than or equal to 110), Tachynpnea (RR greater than or equal to 20),Temperature greater than or equal to 38.5 degrees Celsius or less than or equal to 36 degrees Celsius. Age greater than or equal to 6: Tachycardia(HR greater than or equal to 90), Tachynpnea (RR greater than or equal to 20), Temperature greater than or equal to 38.5 degrees Celsius or less than or equal to 36 degrees Celsius.
D. Ability of the subject or legally authorized representative/parent to understand study procedures, and willing and able to comply with all required.
Exclusion Criteria:
A. Known or suspected infection at any other anatomic site requiring antibacterial therapy.
B. Any specific condition that in the judgment of the referring provider or the site investigator precludes participation because it could affect subject safety or ability of subject to participate in this trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Subjects with Acute Respiratory Illness
Patients with acute respiratory illness identified in the Emergency Department
|
comparison to retrospective clinical adjudication
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Positive predictive value with reference standard (PPV)
Lasso di tempo: Day 1
|
Number of assay positives that agree with the reference standard / [Number of assay positives that agree with the reference standard + Number of assay positives that disagree with the reference standard]
|
Day 1
|
Negative predictive value with the reference standard (NPV)
Lasso di tempo: Day 1
|
Number of assay negatives that agree with the reference standard / [number of assay negatives that agree with the reference standard + number of assay negatives that disagree with the reference standard]
|
Day 1
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Overall agreement with the reference standard (OA)
Lasso di tempo: Day 1
|
Number of samples that agree with the reference standard / all samples tested
|
Day 1
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Pro00082317
- Pro00082322 (Altro identificatore: Duke UMC)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Host Gene Expression
-
Philips Consumer LifestyleCompletato
-
Muğla Sıtkı Koçman UniversityCompletato
-
Nottingham Trent UniversityImperial College London; University of Reading; Clasado Biosciences; HOST Therabiomics e altri collaboratoriCompletatoAsma | Asma indotto dall'esercizioRegno Unito
-
The University of Hong KongRitirato
-
TC Erciyes UniversityCompletatoSano | Disturbo dello spettro autistico | Autismo ad alto funzionamento
-
Fox Chase Cancer CenterNational Cancer Institute (NCI); Columbia University; Temple University; Herbert... e altri collaboratoriNon ancora reclutamento
-
Chiayi Christian HospitalSanofiSconosciuto
-
Histograft Co., Ltd.Moscow State University of Medicine and DentistryCompletatoPerdita di massa ossea | Perdita dei denti | Cisti ossee | Frattura dell'osso | Deformità ossea | Atrofia osseaFederazione Russa
-
Ruijin HospitalRenJi Hospital; West China Hospital; Shandong Provincial Hospital; Tianjin Medical... e altri collaboratoriReclutamentoLinfoma a cellule T perifericheCina
-
Assiut UniversityNon ancora reclutamentoSistema; Lupus eritematoso